Encorafenib Patent Expiration
Encorafenib is Used for treating metastatic non-small cell lung cancer, metastatic colorectal cancer, and melanoma with BRAF mutations. It was first introduced by Array Biopharma Inc
Encorafenib Patents
Given below is the list of patents protecting Encorafenib, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Braftovi | US9474754 | Pharmaceutical combinations comprising a B-RAF inhibitor, and EGFR inhibitor and optionally a PI3K-α inhibitor | Aug 05, 2033 | Array Biopharma Inc |
| Braftovi | US10258622 | Method of treating colorectal cancer by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)pheny1)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl) carbamate | Nov 21, 2032 | Array Biopharma Inc |
| Braftovi | US9387208 | Pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate | Nov 21, 2032 | Array Biopharma Inc |
| Braftovi | US9763941 | Method of treating melanoma by administration of pharmaceutical formulations of (S)-methyl (1-((4-(3-(5-chloro-2-fluoro-3-(methylsulfonamido)phenyl)-1-isopropyl-1H-pyrazol-4-yl)pyrimidin-2-yl)amino)propan-2-yl)carbamate | Nov 21, 2032 | Array Biopharma Inc |
| Braftovi | US9314464 | Compounds and compositions as protein kinase inhibitors | Jul 04, 2031 | Array Biopharma Inc |
| Braftovi | US8501758 | Compounds and compositions as protein kinase inhibitors | Mar 04, 2031 | Array Biopharma Inc |
| Braftovi | US10005761 | Compounds and compositions as protein kinase inhibitors | Aug 27, 2030 | Array Biopharma Inc |
| Braftovi | US8501758 | Compounds and compositions as protein kinase inhibitors | Aug 27, 2030 | Array Biopharma Inc |
| Braftovi | US9593099 | Compounds and compositions as protein kinase inhibitors | Aug 27, 2030 | Array Biopharma Inc |
| Braftovi | US9593100 | Compounds and compositions as protein kinase inhibitors | Aug 27, 2030 | Array Biopharma Inc |
| Braftovi | US9850229 | Compounds and compositions as protein kinase inhibitors | Aug 27, 2030 | Array Biopharma Inc |
| Braftovi | US9850230 | Compounds and compositions as protein kinase inhibitors | Aug 27, 2030 | Array Biopharma Inc |
| Braftovi | USRE49556 | Compounds and compositions as protein kinase inhibitors | Feb 27, 2030 | Array Biopharma Inc |
| Braftovi | US8541575 | 3,4-diarylpyrazoles as protein kinase inhibitors | Feb 26, 2030 | Array Biopharma Inc |
| Braftovi | US8946250 | 3,4-diarylpyrazoles as protein kinase inhibitors | Jul 23, 2029 | Array Biopharma Inc |
Encorafenib's Family Patents
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List